- Home
- AUUD vs PCSA Comparison
AUUD vs PCSA Comparison
Compare AUUD & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- PCSA
- Stock Information
- Founded
- AUUD 2012
- PCSA 2011
- Country
- AUUD United States
- PCSA United States
- Employees
- AUUD N/A
- PCSA N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- PCSA Health Care
- Exchange
- AUUD Nasdaq
- PCSA Nasdaq
- Market Cap
- AUUD 2.7M
- PCSA 2.8M
- IPO Year
- AUUD 2021
- PCSA N/A
- Fundamental
- Price
- AUUD $0.38
- PCSA $0.53
- Analyst Decision
- AUUD
- PCSA Strong Buy
- Analyst Count
- AUUD 0
- PCSA 2
- Target Price
- AUUD N/A
- PCSA $5.00
- AVG Volume (30 Days)
- AUUD 5.0M
- PCSA 508.0K
- Earning Date
- AUUD 03-31-2025
- PCSA 03-28-2025
- Dividend Yield
- AUUD N/A
- PCSA N/A
- EPS Growth
- AUUD N/A
- PCSA N/A
- EPS
- AUUD N/A
- PCSA N/A
- Revenue
- AUUD N/A
- PCSA N/A
- Revenue This Year
- AUUD N/A
- PCSA N/A
- Revenue Next Year
- AUUD N/A
- PCSA N/A
- P/E Ratio
- AUUD N/A
- PCSA N/A
- Revenue Growth
- AUUD N/A
- PCSA N/A
- 52 Week Low
- AUUD $0.38
- PCSA $0.47
- 52 Week High
- AUUD $5.70
- PCSA $3.31
- Technical
- Relative Strength Index (RSI)
- AUUD 39.50
- PCSA 30.16
- Support Level
- AUUD $0.43
- PCSA $0.58
- Resistance Level
- AUUD $0.86
- PCSA $0.71
- Average True Range (ATR)
- AUUD 0.08
- PCSA 0.06
- MACD
- AUUD -0.00
- PCSA 0.00
- Stochastic Oscillator
- AUUD 0.75
- PCSA 0.00
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).